Table 3.
Onset timing of MAEs induced by rosuvastatin and concomitant drugs
| Concomitant drugs | No. of cases (≥30 cases) | MAE onset (days) | IQR | ||||
|---|---|---|---|---|---|---|---|
| Minimum value | First quartile | Median | Third quartile | Maximum value | |||
| Ramipril | 34 | 0.0 | 0.0 | 12.0 | 103.0 | 212.0 | 0.0‐103.0 |
| Olmesartan | 33 | 0.0 | 3.0 | 19.0 | 71.0 | 275.0 | 3.0‐71.0 |
| Lansoprazole | 30 | 0.0 | 0.3 | 25.0 | 147.8 | 357.0 | 0.3‐147.8 |
| Clopidogrel | 94 | 0.0 | 1.0 | 30.0 | 120.0 | 363.0 | 1.0‐120.0 |
| Warfarin | 46 | 0.0 | 1.3 | 30.0 | 69.0 | 317.0 | 1.3‐69.0 |
| Aspirin | 260 | 0.0 | 1.0 | 31.0 | 92.0 | 334.0 | 1.0‐92.0 |
| Atenolol | 61 | 0.0 | 0.0 | 31.0 | 78.0 | 362.0 | 0.0‐78.0 |
| Levothyroxine | 92 | 0.0 | 7.0 | 31.0 | 102.3 | 363.0 | 7.0‐102.3 |
| Candesartan | 31 | 0.0 | 0.5 | 32.0 | 75.5 | 282.0 | 0.5‐75.5 |
| Lisinopril | 79 | 0.0 | 1.5 | 34.0 | 115.5 | 363.0 | 1.5‐115.5 |
| Omeprazole | 90 | 0.0 | 2.3 | 34.5 | 125.5 | 314.0 | 2.3‐125.5 |
| Metformin | 64 | 0.0 | 0.0 | 36.0 | 105.0 | 334.0 | 0.0‐105.0 |
| Acetaminophen | 43 | 0.0 | 1.0 | 37.0 | 101.0 | 286.0 | 1.0‐101.0 |
| Metoprolol | 97 | 0.0 | 1.0 | 38.0 | 148.0 | 349.0 | 1.0‐148.0 |
| Bisoprolol | 35 | 0.0 | 10.5 | 40.0 | 113.0 | 334.0 | 10.5‐113.0 |
| Valsartan | 54 | 0.0 | 2.3 | 40.5 | 143.5 | 359.0 | 2.3‐143.5 |
| Hydrochlorothiazide | 84 | 0.0 | 2.8 | 45.5 | 116.0 | 334.0 | 2.8‐116.0 |
| Amlodipine | 89 | 0.0 | 5.0 | 47.0 | 116.0 | 363.0 | 5.0‐116.0 |
| Esomeprazole | 49 | 0.0 | 1.0 | 47.0 | 224.0 | 314.0 | 1.0‐224.0 |
| Ezetimibe | 44 | 0.0 | 0.8 | 50.0 | 117.5 | 258.0 | 0.8‐117.5 |
| Furosemide | 65 | 0.0 | 10.0 | 55.0 | 121.0 | 302.0 | 10.0‐121.0 |
| Fluticasone | 30 | 0.0 | 0.5 | 62.5 | 144.0 | 353.0 | 0.5‐144.0 |
The Steel test was performed for cases of the rosuvastatin monotherapy group (n = 413) as the control group. IQR, interquartile range; MAEs, musculoskeletal adverse events.